Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Malorni L, et al. Among authors: curigliano g. Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214. Ann Oncol. 2018. PMID: 29893790 Free PMC article. Clinical Trial.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
Biosimilars for breast cancer.
Migliavacca Zucchetti B, Nicolò E, Curigliano G. Migliavacca Zucchetti B, et al. Among authors: curigliano g. Expert Opin Biol Ther. 2019 Oct;19(10):1015-1021. doi: 10.1080/14712598.2019.1638362. Epub 2019 Jul 10. Expert Opin Biol Ther. 2019. PMID: 31248290 Review.
Evaluating triptorelin as a treatment option for breast cancer.
Ferraro E, Trapani D, Marrucci E, Curigliano G. Ferraro E, et al. Among authors: curigliano g. Expert Opin Pharmacother. 2019 Oct;20(15):1809-1818. doi: 10.1080/14656566.2019.1650020. Epub 2019 Sep 9. Expert Opin Pharmacother. 2019. PMID: 31500470
Pharmacological management of male breast cancer.
Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Duso BA, et al. Among authors: curigliano g. Expert Opin Pharmacother. 2020 Aug;21(12):1493-1504. doi: 10.1080/14656566.2020.1763305. Epub 2020 Jun 4. Expert Opin Pharmacother. 2020. PMID: 32496137 Review.
Management of Cardiac Toxicity Induced by Chemotherapy.
Trapani D, Zagami P, Nicolò E, Pravettoni G, Curigliano G. Trapani D, et al. Among authors: curigliano g. J Clin Med. 2020 Sep 7;9(9):2885. doi: 10.3390/jcm9092885. J Clin Med. 2020. PMID: 32906611 Free PMC article. Review.
847 results